TSHATaysha Gene Therapies, Inc. Common Stock

CSNasdaq (XNAS)·USD

Identity

Security key: 22788
Ticker: TSHA
Type: CS — Common Stock
Exchange: Nasdaq(XNAS)
Venue group: NASDAQ
Operating MIC: XNAS
Market: stocks
Locale: us
Currency: USD
Listed: 2020-09-24
Round lot: 100
Active: Yes
Last seen in a load: 2026-08-14 20:49
Vendor updated: 2026-08-13 06:09
Ticker root / suffix: TSHA

Detail

Enriched 2026-08-14 20:47

Market cap: $2,048,709,839.51
Shares outstanding (class): 287,361,020
Shares outstanding (weighted): 319,861,021
SIC: 2836 BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Employees: 99
Location: DALLAS, TX
Homepage: https://www.tayshagtx.com
Description: Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.

Market cap and share counts drift.

Funds holding this security

72 funds · 73 positions · $137.33M reported value, as of 2026-03-31

All holders →

Fund	Ticker	Position value	% of fund	Balance	Match
VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS	VTI	$33.59M	0.00%	7,513,950 NS	FIGI
State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST	XBI	$25.21M	0.34%	5,638,911 NS	FIGI
iShares Russell 2000 ETF iShares Trust	IWM	$24.19M	0.03%	5,410,999 NS	FIGI
VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS	VXF	$11.08M	0.01%	2,478,922 NS	FIGI
iShares Russell 2000 Growth ETF iShares Trust	IWO	$8.02M	0.07%	1,793,905 NS	FIGI
iShares Biotechnology ETF iShares Trust	IBB	$7.47M	0.09%	1,672,180 NS	FIGI
abrdn Life Sciences Investors —	—	$4.56M	0.81%	1,021,063 NS	FIGI
Fidelity Enhanced Small Cap ETF Fidelity Covington Trust	FESM	$3.26M	0.08%	729,281 NS	FIGI
State Street(R) SPDR(R) S&P Kensho New Economie… SPDR SERIES TRUST	KOMP	$2.68M	0.11%	598,759 NS	FIGI
iShares Micro-Cap ETF iShares Trust	IWC	$2.49M	0.20%	556,551 NS	FIGI
Master Small Cap Index Series Quantitative Master Series LLC	—	$1.52M	0.03%	340,182 NS	FIGI
iShares Core S&P Total U.S. Stock Market ETF iShares Trust	ITOT	$1.44M	0.00%	321,904 NS	FIGI
EQ/2000 Managed Volatility Portfolio EQ Advisors Trust	—	$1.01M	0.03%	225,292 NS	FIGI
Fidelity Small Cap Growth Index Fund Fidelity Salem Street Trust	—	$750.5K	0.07%	167,898 NS	FIGI
Clearwater Select Equity Fund Clearwater Investment Trust	—	$704.1K	0.16%	157,524 NS	FIGI

How positions resolve to the securities master. FIGI_COMPOSITE is exact identifier equality — both sides got the FIGI from Bloomberg. TICKER is a narrow fallback used only where the master row carries no FIGI at all (2,389 rows do not, disproportionately Irish-domiciled US listings like LIN and ACN). Roughly 22% of all positions resolve to the master.

Funds holding this security

Identifiers

master.security_identifier

TICKERTSHA
FIGI_COMPOSITEBBG00TJXFDP1
FIGI_SHARE_CLASSBBG00TJXFDQ0
CIK0001806310
ISINUS8776191061
Resolved through OpenFIGI from a holdings ISIN, not supplied by the securities vendor.

Identifiers

Classification

classification.v_security_classification

Asset class: Equity
Sector: Health Care
Industry: Biotechnology
Source: LLMunreviewed
Self-reported confidence: 0.95
Model: deepseek
Rationale: Taysha Gene Therapies is a biopharmaceutical company developing gene therapies, fitting the biotechnology industry under healthcare.

Classifications are unreviewed model output. All 5,771 assignments carry source = LLM and is_reviewed = false. Confidence is the model’s own estimate and is not calibrated — it clustered at 0.90–0.98 across the whole first pass, including rows that later proved wrong. Use it to order a review queue, not as a probability. Two share classes of one issuer can disagree.

Classification

Fund data

Not linked to a fund series.

Either this is not a fund, or it is one the SEC share-class snapshot cannot reach — commodity trusts and notes have no series ID at all.